$プロキューアール・セラピューティクス(PRQR.US)$ NEWS ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
ProQR Therapeutics' short term liquidity and more cash than debt suggest it can manage its debt safely. Its 38% revenue growth is a positive sign, indicating potential for further strong growth.
Pharma industry has been doing well despite the recession, and I believe these companies will continue to do well moving forward (they have upcoming catalysts in q1/h1 2023) 1.$バイキング・セラピューティクス(VKTX.US)$closest competitor to$マドリガル・ファーマシューティカルズ(MDGL.US)$, which recently announced breakthroughs in the NASH space and price went up ×4 times. multiple catalysts in 2023 q1. 2.$プロキューアール・セラピューティクス(PRQR.US)$announced collaboration with LLY, their RNAI editing softwa...
$プロキューアール・セラピューティクス(PRQR.US)$Yesterday we didn't break the $3 resistance! I believe today we will! Price target up from $2 to $5! Shifted from Neutral to Overweight!💪🏻
$プロキューアール・セラピューティクス(PRQR.US)$easy. easy. Good news worth 3.75B✅ $2+ lesser commission if you compare to those few cents stock ✅ Good news in a NO NEWS market ✅ if this don't go pass $5 then nth much I can say about it
プロキューアール・セラピューティクスに関するコメント
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
ProQR Therapeutics Highlights New Platform Data From Presentation On Axiomer RNA Editing Technology, Company Says Platform Demonstrates Robust In Vivo Editing Capabilities Reporting Up To 70% Editing
Long Term Pharma Holds
1. $バイキング・セラピューティクス(VKTX.US)$ closest competitor to $マドリガル・ファーマシューティカルズ(MDGL.US)$ , which recently announced breakthroughs in the NASH space and price went up ×4 times. multiple catalysts in 2023 q1.
2. $プロキューアール・セラピューティクス(PRQR.US)$ announced collaboration with LLY, their RNAI editing softwa...
AH + 12/23 watchlist
$AMCエンターテインメント クラスA(AMC.US)$$アプテック・ペイメンツ(APCX.US)$$Core Scientific(CORZ.US)$$iMedia Brands(IMBI.US)$$カーマックス(KMX.US)$$メルサナ・セラピューティクス(MRSN.US)$$エヌビディア(NVDA.US)$$ORICファーマシューティカルズ(ORIC.US)$$プロキューアール・セラピューティクス(PRQR.US)$$ロケット・ファーマシューティカルズ(RCKT.US)$$ロク(ROKU.US)$$キャッサバ・サイエンシズ(SAVA.US)$$テスラ(TSLA.US)$$エクスピオン360(XPON.US)$
22/12: Let's go!!
まだコメントはありません